Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday

Kodiak Sciences (NASDAQ:KOD) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.06. On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $4.03 on Wednesday. The stock has a market cap of $212.59 million, a price-to-earnings ratio of -1.10 and a beta of 2.42. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $11.60. The business has a fifty day moving average of $3.29 and a 200-day moving average of $5.50.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.